HCW Biologics (NASDAQ:HCWB) Trading 9.1% Higher – Still a Buy?

Shares of HCW Biologics Inc. (NASDAQ:HCWB) traded up 9.1% during mid-day trading on Friday . The company traded as high as $10.00 and last traded at $8.95. 350,959 shares changed hands during trading, an increase of 37% from the average session volume of 256,073 shares. The stock had previously closed at $8.20.

HCW Biologics Stock Performance

The stock’s 50-day moving average price is $9.42 and its 200-day moving average price is $14.46. The company has a market capitalization of $10.05 million, a price-to-earnings ratio of -8.95 and a beta of 0.85.

HCW Biologics (NASDAQ:HCWB) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.05) earnings per share (EPS) for the quarter. HCW Biologics had a negative net margin of 1,067.82% and a negative return on equity of 2,516.84%.

Insider Transactions at HCW Biologics

In other news, Director Gary M. Winer bought 2,308 shares of the stock in a transaction on Thursday, May 8th. The stock was purchased at an average cost of $26.00 per share, with a total value of $60,008.00. Following the purchase, the director now owns 2,733 shares of the company’s stock, valued at approximately $71,058. The trade was a 543.06% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CFO Rebecca Byam bought 8,462 shares of the stock in a transaction on Thursday, May 8th. The stock was purchased at an average cost of $26.00 per share, with a total value of $220,012.00. Following the completion of the purchase, the chief financial officer now directly owns 43,010 shares in the company, valued at $1,118,260. This trade represents a 24.49% increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 11,732 shares of company stock valued at $305,032 in the last ninety days. Corporate insiders own 49.90% of the company’s stock.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.